Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

On demand therapy for Parkinson’s disease patients: Opportunities and choices
Robert A. Hauser, Peter A. LeWitt, Cynthia L. Comella
Postgraduate Medicine (2021) Vol. 133, Iss. 7, pp. 721-727
Open Access | Times Cited: 18

Showing 18 citing articles:

Closing the loop for patients with Parkinson disease: where are we?
Hazhir Teymourian, Farshad Tehrani, Katherine Longardner, et al.
Nature Reviews Neurology (2022) Vol. 18, Iss. 8, pp. 497-507
Closed Access | Times Cited: 50
An update on pathogenesis and clinical scenario for Parkinson’s disease: diagnosis and treatment
Hussaini Adam, Subash C. B. Gopinath, M. K. Md Arshad, et al.
3 Biotech (2023) Vol. 13, Iss. 5
Open Access | Times Cited: 25
IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease
Robert A. Hauser, Alberto J. Espay, Aaron Ellenbogen, et al.
JAMA Neurology (2023) Vol. 80, Iss. 10, pp. 1062-1062
Open Access | Times Cited: 12
Metformin Effect Against Rotenone-Induced Parkinsonism-Like Symptoms in a Mouse Model
Israa Hussein Al-Mammory, Ghaith Ali Jasim, Wassan Abdulkareem Abbas
Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ) (2025) Vol. 8, Iss. 2, pp. 47-52
Closed Access
A Novel and Selective Dopamine Transporter Inhibitor, (S)-MK-26, Promotes Hippocampal Synaptic Plasticity and Restores Effort-Related Motivational Dysfunctions
Shima Kouhnavardi, Alev Ecevitoglu, Vladimir Dragačević, et al.
Biomolecules (2022) Vol. 12, Iss. 7, pp. 881-881
Open Access | Times Cited: 18
Inhaled levodopa for threatening impending OFF episodes in managing Parkinson’s disease
Wolfgang H. Jost, Jaime Kulisevsky, Peter A. LeWitt
Journal of Neural Transmission (2023) Vol. 130, Iss. 6, pp. 821-826
Closed Access | Times Cited: 9
Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier?
Stuart Isaacson, Fernando Pagán, Mark Lew, et al.
Clinical Parkinsonism & Related Disorders (2022) Vol. 7, pp. 100161-100161
Open Access | Times Cited: 11
Revisiting the Effect of Leptin on Alzheimer Disease and Parkinson Disease: The Role of Insulin Sensitivity
Xingzhi Guo, Peng Tang, Xin Zhang, et al.
The Journal of Clinical Endocrinology & Metabolism (2024) Vol. 109, Iss. 9, pp. 2274-2281
Closed Access | Times Cited: 2
Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson’s disease complicated by OFF episodes: a phase 3, open-label study
Jan Kassubek, Stewart A. Factor, Ernest Balaguer, et al.
Journal of Neurology (2024) Vol. 271, Iss. 6, pp. 3554-3570
Open Access | Times Cited: 2
Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson’s Disease
Xiao‐Zhong Jing, Huijia Yang, Reyisha Taximaimaiti, et al.
Current Neuropharmacology (2022) Vol. 21, Iss. 5, pp. 1224-1240
Open Access | Times Cited: 11
Expert Consensus on the Use of On‐Demand Treatments for OFF Episodes in Parkinson's Disease: A Modified Delphi Panel
Stuart Isaacson, Madhureeta Achari, Roongroj Bhidayasiri, et al.
Movement Disorders Clinical Practice (2023) Vol. 10, Iss. 4, pp. 652-657
Open Access | Times Cited: 4
Clinical Use of On-Demand Therapies for Patients with Parkinson’s Disease and OFF Periods
Rajesh Pahwa, Fernando Pagán, Daniel Kremens, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 4, pp. 1033-1049
Open Access | Times Cited: 4
Impact of Off-Time on Quality of Life in Parkinson’s Patients and Their Caregivers: Insights from Social Media
Philippe Damier, Emily J. Henderson, Jesús Romero-Imbroda, et al.
Parkinson s Disease (2022) Vol. 2022, pp. 1-11
Open Access | Times Cited: 4
Motor Response With Apomorphine Sublingual Film and Levodopa in Patients With OFF Episodes
Stuart Isaacson, Alyssa Bowling, Ian Zhang, et al.
Neurodegenerative Disease Management (2022) Vol. 13, Iss. 2, pp. 75-84
Open Access | Times Cited: 4
Hope vs. Hype III: Rescue/on-demand therapies are preferable to device-assisted therapies in Parkinson disease
Stuart Isaacson, Oliver Phillips, Joohi Jimenez‐Shahed
Parkinsonism & Related Disorders (2024) Vol. 126, pp. 106079-106079
Closed Access
Levodopa inhalada: de la evidencia a la experiencia
Juan Carlos Martínez‐Castrillo, Isabel Parees-Moreno, J L López Sendón-Moreno, et al.
Revista de Neurología (2024) Vol. 78, Iss. S01, pp. S1-S1
Closed Access
ADMINISTRATION OF LEVODOPA IN A PARKINSON’S PATIENT USING A NOVEL ORAL AND MAXILLOFACIAL ROUTE – A FIRST IN HUMAN STUDY
Suresh Thirunavukarasu, Balasubramanian Bala Venkata Ramanan, Sathya Krishnan Suresh, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
The Administration of Levodopa in a Patient With Parkinson’s Disease Using a Novel Maxillofacial Route: A First-in-Human Report
Suresh Thirunavukarasu, Balasubramanian Bala Venkata Ramanan, Sathya Krishnan Suresh, et al.
Cureus (2023)
Open Access | Times Cited: 1
Page 1

Scroll to top